source
- J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolioJohnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
- BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric ModelBridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…